230 related articles for article (PubMed ID: 16078104)
1. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells.
McAllister SD; Chan C; Taft RJ; Luu T; Abood ME; Moore DH; Aldape K; Yount G
J Neurooncol; 2005 Aug; 74(1):31-40. PubMed ID: 16078104
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol.
Romero J; Berrendero F; García-Gil L; Ramos JA; Fernández-Ruiz JJ
J Mol Neurosci; 1998 Oct; 11(2):109-19. PubMed ID: 10096037
[TBL] [Abstract][Full Text] [Related]
3. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
Sim-Selley LJ; Martin BR
J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
[TBL] [Abstract][Full Text] [Related]
4. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
5. Effects of delta9-THC and WIN-55,212-2 on place preference in the water maze in rats.
Robinson L; Hinder L; Pertwee RG; Riedel G
Psychopharmacology (Berl); 2003 Feb; 166(1):40-50. PubMed ID: 12488948
[TBL] [Abstract][Full Text] [Related]
6. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.
Pertwee RG; Stevenson LA; Griffin G
Br J Pharmacol; 1993 Dec; 110(4):1483-90. PubMed ID: 8306090
[TBL] [Abstract][Full Text] [Related]
7. Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212.
Fan F; Compton DR; Ward S; Melvin L; Martin BR
J Pharmacol Exp Ther; 1994 Dec; 271(3):1383-90. PubMed ID: 7996450
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice.
McMahon LR; Ginsburg BC; Lamb RJ
Psychopharmacology (Berl); 2008 Jul; 198(4):487-95. PubMed ID: 17673980
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism.
Chen Y; Buck J
J Pharmacol Exp Ther; 2000 Jun; 293(3):807-12. PubMed ID: 10869379
[TBL] [Abstract][Full Text] [Related]
10. Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain.
Sim LJ; Hampson RE; Deadwyler SA; Childers SR
J Neurosci; 1996 Dec; 16(24):8057-66. PubMed ID: 8987831
[TBL] [Abstract][Full Text] [Related]
11. Role of cannabinoid CB1 receptors and Gi/o protein activation in the modulation of synaptosomal Na+,K+-ATPase activity by WIN55,212-2 and delta(9)-THC.
Araya KA; David Pessoa Mahana C; González LG
Eur J Pharmacol; 2007 Oct; 572(1):32-9. PubMed ID: 17644088
[TBL] [Abstract][Full Text] [Related]
12. Delta9-tetrahydrocannabinol protects hippocampal neurons from excitotoxicity.
Gilbert GL; Kim HJ; Waataja JJ; Thayer SA
Brain Res; 2007 Jan; 1128(1):61-9. PubMed ID: 17140550
[TBL] [Abstract][Full Text] [Related]
13. [Drug discrimination properties and cytotoxicity of the cannabinoid receptor ligands].
Tomiyama K; Funada M
Nihon Arukoru Yakubutsu Igakkai Zasshi; 2012 Jun; 47(3):135-43. PubMed ID: 22894054
[TBL] [Abstract][Full Text] [Related]
14. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.
Guzmán M; Duarte MJ; Blázquez C; Ravina J; Rosa MC; Galve-Roperh I; Sánchez C; Velasco G; González-Feria L
Br J Cancer; 2006 Jul; 95(2):197-203. PubMed ID: 16804518
[TBL] [Abstract][Full Text] [Related]
15. The cannabinoid agonist WIN 55,212-2 inhibits TNF-alpha-induced neutrophil transmigration across ECV304 cells.
Nilsson O; Fowler CJ; Jacobsson SO
Eur J Pharmacol; 2006 Oct; 547(1-3):165-73. PubMed ID: 16928371
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of monoamine oxidase activity by cannabinoids.
Fisar Z
Naunyn Schmiedebergs Arch Pharmacol; 2010 Jun; 381(6):563-72. PubMed ID: 20401651
[TBL] [Abstract][Full Text] [Related]
17. Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation.
Hoffman AF; Oz M; Yang R; Lichtman AH; Lupica CR
Learn Mem; 2007; 14(1-2):63-74. PubMed ID: 17202425
[TBL] [Abstract][Full Text] [Related]
18. Protective effects of Delta(9)-tetrahydrocannabinol against N-methyl-d-aspartate-induced AF5 cell death.
Chen J; Lee CT; Errico S; Deng X; Cadet JL; Freed WJ
Brain Res Mol Brain Res; 2005 Apr; 134(2):215-25. PubMed ID: 15836919
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide.
Facchinetti F; Del Giudice E; Furegato S; Passarotto M; Leon A
Glia; 2003 Jan; 41(2):161-8. PubMed ID: 12509806
[TBL] [Abstract][Full Text] [Related]
20. A combined preclinical therapy of cannabinoids and temozolomide against glioma.
Torres S; Lorente M; Rodríguez-Fornés F; Hernández-Tiedra S; Salazar M; García-Taboada E; Barcia J; Guzmán M; Velasco G
Mol Cancer Ther; 2011 Jan; 10(1):90-103. PubMed ID: 21220494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
